MedTrace Logo

The Pharmacokinetic Interaction Between Celecoxib and Rebamipide

NCT01549743 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-17

No results posted yet for this study

Summary

This clinical trial aims to assess the pharmacokinetic interaction between celecoxib and rebamipide in healthy male subjects.

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

Celecoxib

Celecoxib 200mg will be administered orally twice a day for 3 days

DRUG

Rebamipide

Rebamipide 100mg will be administered orally three times a day for 3 days

DRUG

Celecoxib plus Rebamipide

Celecoxib plus Rebamipide same way as "arm: celecoxib" and "arm: rebamipide"

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ji Young Park, Ph.D. · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-09
Primary Completion
2012-06-13
Completion
2012-06-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01549743 on ClinicalTrials.gov